​

X4 Pharmaceuticals (XFOR) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

XFOR Stock Forecast

X4 Pharmaceuticals (XFOR) stock forecast, based on 13 Wall Street analysts, predicts a 12-month average price target of $3.67, with a high of $5.00 and a low of $3.00. This represents a 14.33% increase from the last price of $3.21.

- $1 $2 $3 $4 $5 High: $5 Avg: $3.67 Low: $3 Last Closed Price: $3.21

XFOR Stock Rating

X4 Pharmaceuticals stock's rating consensus is Buy, based on 13 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (92.31%), 1 Hold (7.69%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 13 1 12 0 Strong Sell Sell Hold Buy Strong Buy

XFOR Price Target Upside V Benchmarks

TypeNameUpside
StockX4 Pharmaceuticals14.33%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.21$3.21$3.21
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2523---5
May, 2523---5
Apr, 2523---5
Mar, 2523---5
Feb, 2523---5
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 22, 2022Cantor Fitzgerald$3.00$0.85252.94%-6.54%
Dec 11, 2022Edward TenthoffPiper Sandler$3.00$0.93222.58%-6.54%
Nov 30, 2022H.C. Wainwright$5.00$1.85170.27%55.76%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 28, 2024H.C. WainwrightBuyBuyhold
Dec 22, 2022Cantor FitzgeraldOverweightinitialise
Dec 11, 2022Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.09$-0.57$-0.19----
Avg Forecast$-3.11$-0.61$-0.14$-0.56$-0.36$-0.05$0.01
High Forecast$-0.01$-0.60$-0.12$-0.39$-0.28$0.26$0.01
Low Forecast$-11.11$-0.63$-0.15$-0.74$-0.49$-0.28-
Surprise %-0.64%-6.56%35.71%----

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.00M-$2.56M----
Avg Forecast$3.00M-$2.19M$21.55M$61.06M$142.21M$174.01M
High Forecast$8.94M-$2.59M$28.42M$61.60M$144.03M$238.73M
Low Forecast$701.95K-$1.96M$11.10M$60.52M$140.38M$85.73M
Surprise %--16.61%----

Net Income Forecast

$-2B $-2B $-1B $-500M $0 $500M Dec 20 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-62.13M$-101.17M$-37.45M----
Avg Forecast$-553.03M$-109.33M$-23.54M$-101.02M$-68.48M$-33.57M$1.78M
High Forecast$-2.31M$-106.74M$-21.26M$-69.61M$-49.97M$46.30M$2.64M
Low Forecast$-1.98B$-111.91M$-25.82M$-132.42M$-86.99M$-49.29M$605.45K
Surprise %-88.77%-7.46%59.07%----

XFOR Forecast FAQ

Is X4 Pharmaceuticals stock a buy?

X4 Pharmaceuticals stock has a consensus rating of Buy, based on 13 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that X4 Pharmaceuticals is a favorable investment for most analysts.

What is X4 Pharmaceuticals's price target?

X4 Pharmaceuticals's price target, set by 13 Wall Street analysts, averages $3.67 over the next 12 months. The price target range spans from $3 at the low end to $5 at the high end, suggesting a potential 14.33% change from the previous closing price of $3.21.

How does X4 Pharmaceuticals stock forecast compare to its benchmarks?

X4 Pharmaceuticals's stock forecast shows a 14.33% upside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for X4 Pharmaceuticals over the past three months?

  • June 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 40.00% Strong Buy, 60.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is X4 Pharmaceuticals’s EPS forecast?

X4 Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.56, marking a 194.74% increase from the reported $-0.19 in 2024. Estimates for the following years are $-0.36 in 2026, $-0.05 in 2027, and $0.01 in 2028.

What is X4 Pharmaceuticals’s revenue forecast?

X4 Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $21.55M, reflecting a 742.61% increase from the reported $2.56M in 2024. The forecast for 2026 is $61.06M, followed by $142.21M for 2027, and $174.01M for 2028.

What is X4 Pharmaceuticals’s net income forecast?

X4 Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $-101M, representing an 169.74% increase from the reported $-37.45M in 2024. Projections indicate $-68.484M in 2026, $-33.566M in 2027, and $1.78M in 2028.